SCHEMBL5118580

SCHEMBL5118580

COc1ccc(CNc2nc(-c3cccnc3)nc3scc(C)c23)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
HPGD P15428 1/20 0.55
MAPT P10636 7/20 0.52
CYP1A2 P05177 5/20 0.52
CYP3A4 P08684 5/20 0.52
CYP2D6 P10635 5/20 0.52
CYP2C19 P33261 5/20 0.52
CYP2C9 P11712 3/20 0.52
KMT2A Q03164 6/20 0.50
MEN1 O00255 5/20 0.50
LMNA P02545 5/20 0.47
USP2 O75604 4/20 0.47
TSHR P16473 4/20 0.47
MAPK1 P28482 4/20 0.47
HSD17B10 Q99714 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HIF1A Q16665 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PDE5A O76074 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5809020 0.95 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HPGDMAPTCYP1A2
SCHEMBL5122543 0.92 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2HPGDMAPTCYP1A2
SCHEMBL5119865 0.89 MEN1 (0.52) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL7516802 0.89 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDMAPTCYP1A2
SCHEMBL5124327 0.85 TNF (0.44) ALDH1A1SMN1; SMN2HPGDMAPTCYP1A2
SCHEMBL5130058 0.85 KMT2A (0.50) ALDH1A1SMN1; SMN2HPGDMAPTCYP1A2
SCHEMBL5115819 0.85 CLK4 (0.54) ALDH1A1SMN1; SMN2HPGDMAPTCYP1A2
SCHEMBL5116120 0.84 POLB (0.58) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP3A4
SCHEMBL7522368 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HPGDMAPTKMT2A
SCHEMBL5122209 0.84 PDE5A (0.61) ALDH1A1HPGDMAPTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ALDH1A1 1055/4885SMN1; SMN2 3222/4885HPGD 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.